Medical Professionals

Transforming the future of cancer care

RPx is a next-generation HSV‑1 – based oncolytic immunotherapy platform. RPx can be injected into most lesions, including both superficial and deep lesions, which may afford the opportunity to target distinct tumor and immune microenvironments, maximize anti-tumor activity and immune stimulation.

Research and Educational Support

IST Requests

We are committed to supporting independent research to address areas of medical need and further investigate the safety/efficacy of our oncolytic immunotherapies. Independent research is conducted through our Investigator Sponsored Trial (IST) program. Our IST program is open to physicians, researchers, academic centers, and cooperative groups that are interested in conducting independent clinical research. Contact the team to learn more or submit a Letter of Intent (LOI).*

ISTresearch@replimune.com

Field MSL Team

Interested in connecting with a medical science liaison about Replimune, our clinical programs or data?

medinfo@replimune.com

CME Grants

We are committed to cancer research and treatment using oncolytic immunotherapy approaches. Under Replimune’s CME program, Replimune may provide funding to eligible applicants requesting support for unbiased, evidence-based, independent medical education activities targeting unmet educational needs in the areas of interest to the company.

Full Grant Application

* Submission of a request does not indicate that Replimune has agreed to fund your request. Decisions regarding funding are made only after the company has received and reviewed your complete request. You will be notified of the decision via an email sent to the address you provide upon registration. All decisions are final and in the complete discretion of Replimune.